Short answer
REGENXBIO Inc. (RGNX) filed an 8-K current report with the SEC on August 24, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). FDA clinical hold on RGX-121 Phase I/II/III trial for MPS II, also known as Hunter Syndrome.
REGENXBIO Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- FDA clinical hold on RGX-121 Phase I/II/III trial for MPS II, also known as Hunter Syndrome
- No near-term resubmission expected for RGX-121 BLA, delaying potential regulatory approval
- Material setback for RGX-121 development timeline and near-term commercial prospects
- Full company rationale and implications in Exhibit 99.1 press release
Item 8.01 · Other Events
- FDA clinical hold on RGX-121 Phase I/II/III trial for MPS II
- Near-term RGX-121 BLA resubmission no longer expected
- Development and regulatory timelines materially delayed for RGX-121
- Potential impact on RGX-121 commercialization prospects and valuation beyond the disclosed event
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other REGENXBIO Inc. 8-K filings
Get the next RGNX 8-K as it lands
Follow RGNX for push alerts, or ask the research agent what this filing means.